Scancell Share Discussion Threads

[inanaco] 19/4/2023 11:19

one thing i find so strange ... why are folks desperate for information which is incomplete ?

a course of Modi1 takes about 6 months ...

a course of keytruda can take 12 months .... to 24 months ..

we already know it works .... just don't know yet how well ....

if this was a Motor it would be classed as 18p behind book .... (trinity)

just buy it ... Rucks talking about a £1 ... but his bid at 15p failed ...

LOL

[inanaco] 19/4/2023 11:02

Tf look again ... correction u found it

[torquayfan] 19/4/2023 10:19

Thanks Marcus.

[marcusl2] 19/4/2023 10:11

Results;

Vaccinations have been well tolerated with 71 adverse reactions in 15
pts reported. All were Grade 1 or 2 except for four Grade 3 reactions
in 3 pts (anemia, fatigue, and injection site reactions). There have
been no SAEs. Elevation in anti-CCP antibodies has not been seen.


(it was a theoretical concern about rheumatoid arthritis)

[torquayfan] 19/4/2023 10:04

Inan - ref.3877 and your comment - 'awesome'.

Where did that come from please ? (I looked on the Poster)

ATB

[golcheja] 19/4/2023 09:52

Poster is a complete repeat of published info. It seems poster plus cost equals to -3p.

[inanaco] 19/4/2023 09:46

Its not just a phone anymore Loz ... things have moved on from the Motorola Brick

you really should call it, an ultra mini laptop hand held

[the real lozan] 19/4/2023 09:38

May I ask =
It might seem to be a 'silly' question.but I assure everyone there is LOGIC behind my asking - Am I the ONLY person who frequents these forums....
To NOT have / REFUSE to have - A mobile/portable phone ???
OR
See a good reason NOT to have one

[octopus100] 19/4/2023 09:33

Was there anything extra announced at the AACR over and above what is already known in the public domain prior to yesterday?

[panama7] 19/4/2023 08:36

Looks like a cover up on Moderna's mRNA vax being Carcinogenic. Is this good news for Scancell, I would have thought so.....

[willoicc] 19/4/2023 08:19

£1 is still less than £1bn market cap and would still be derisory if Scancell's trial results prove to be effective in ridding the world of the scourge of cancer.

Of course, there are always people who want to buy companies on the cheap.

[marcusl2] 19/4/2023 08:06

Yes Inan, very safe so far. We know that CPIs have side effects



I am looking forward to Cohort 4 results.

Cohort 1 low dose Modi-1

Cohort 2 high dose Modi-1

Cohort 3 Modi-1 plus CPI Low dose

Cohort 4 Modi-1 plus CPI High dose

Our best known patient withh 55% shrinkage is on Cohort 2.

[markingtime] 19/4/2023 08:06

The bottom line here is that a deal only happens if Vulpes, Redmile and the Scancell Board are all on board with it.In other words, an offer that fails to satisfy all of them won't be put to shareholders as it cannot succeed.My view isn't dissimilar to yours - any deal would be at £1+, irrespective of the pre-deal market price of the shares.

[ruckrover] 19/4/2023 07:10

MT,True, but the current share price when the comment was made was 16p. They may consider 1GBP fair value.Besides, Vulpes and the board would not have enough votes to stop it. Redmile plus Pis would have enough votes to decide either way.

[markingtime] 19/4/2023 06:46

Thats the "strange" thing about M&A....:-))The obligation on the Board is a bit more complicated than that. Practically speaking, a buyer would want a board recommendation - and we know that the holder of 15% considers the current share price "derisory".

[inanaco] 19/4/2023 06:35

awesome .... that was probably the biggest risk ...


"" Elevation in anti-CCP antibodies has not been seen ""

[888icb] 18/4/2023 23:35

People seem to be forgetting that SCLP has shown its ability to do deals that will commercialise its research. This is an extract from an RNS in October 2022:
“ Scancell signs Commercial License Agreement with Genmab



Genmab granted worldwide license to anti-glycan monoclonal antibody generated via Scancell's proprietary GlyMab® platform, for the development and commercialisation of novel therapeutic products



Scancell to receive from Genmab an upfront payment as well as potential milestone payments of up to $208 million for each product developed and commercialised, up to a maximum of $624 million if Genmab develops and commercialises products across all defined modalities. Scancell will also receive low single digit royalties from Genmab on net sales of all commercialised products.



Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, today announces a licensing agreement with Genmab (NASDAQ: GMAB), an international biotechnology company, to develop and commercialise a Scancell investigational anti-glycan monoclonal antibody into novel therapeutic products.”
So that deal alone could bring in multiples of the current market cap. More deals will be happening on several fronts and this is not currently reflected in the share price. Big Pharma will be taking note and could make a move at anytime. The event in Florida is somewhere to get noticed by the big boys.

[panama7] 18/4/2023 22:52

Ruck, you are correct years and years of M & A and Scancell completely bypassed, very strange for a Company that has allegedly had significant interest in it's platforms for years and years.

[ruckrover] 18/4/2023 22:07

My understanding is that if a formal offer is made, the board are obliged to put it to shareholders. If there was a offer of 1GBP, I'd vote to accept. Years and years of M&A activity but none involving Scancell.

[golcheja] 18/4/2023 21:55

Lots of MA activities but no obvious deal in the pipeline for Scan, to be precise not deal as far as we know of. With all what scan has in the pipeline and results so far it’s a puzzle why £1 is not on the table. It could be that scan had an offer but main shareholders want high premium for results based on few dozens of brave participants.

[marcusl2] 18/4/2023 21:38

Moody’s Investor Services thinks these are just the start, with M&A activity expected to remain high over the next year to 18 months. Pharmas are trying to restock their pipelines due to approaching patent cliffs and long-term pricing pressure, Moody’s wrote in a Monday sector commentary note."

[marcusl2] 18/4/2023 21:37

Early week 8 imaging data in the Modi-1 alone dose
escalation and expansion cohorts is encouraging ,demonstrating the
potential for Modi-1 to stabilize and shrink tumors in a sub-group of
patients that have otherwise exhausted most lines of therapy.

[octopus100] 18/4/2023 18:09

How nice would it be to present the poster and then add in the comment we are all looking for that since February - further trialists have experienced a positive reaction.

[ivyspivey] 18/4/2023 17:29

Yep P7,
RG covering his bases by jumping horses but still guaranteed a great payday here whatever happens due to those options.

[panama7] 18/4/2023 17:11

Inane, that is the totally unathletic sport you would play along with tiddlywinks and darts. What do you think of Pfizer CEO stating that 1 in 3 people will get cancer. Do you think that statement could be linked to a few billion people being injected with mRNA or do you think he is a conspiracy theorist. Got to be good news for Scancell if his forecast is correct.